Is there still too much risk surrounding this business?In just the past 12 months, Novavax (NVAX 0.94%) stock has plummeted 48% in value. The once-promising COVID vaccine maker has struggled mightily; it was late to getting a vaccine approved and to market, and now with some concerns relating to COVID subsiding, its near-term prospects haven't been looking good, either.But with the healthcare stock down more than 60% from its 52-week high of $11.36 and at a market cap of around $620 million, has the stock b ...